Role of immune complexes in thyroid diseases

Institute of Biochemistry, Academy of Sciences of the Uzbek SSR, Tashkent. (Presented by Academician of the Academy of Medical Sciences of the USSR Yu. A. Pankov.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 113, No. 2, pp. 168–170, February, 1992.     

抗蚊媒中肠抗体对冈比亚按蚊生殖率和死亡率影响的研究

目的探讨冈比亚按蚊中肠抗原抗媒介免疫的作用,进一步研究抗媒介疫苗抗原. 方法解剖室内饲养的冈比亚按蚊雌蚊中肠,立即置于冷的pH 7.4 PBS溶液中,用SDS-PAGE方法获得分子质量为43 ku中肠蛋白抗原,皮下注射免疫大白兔3次,获得的免疫血浆膜饲冈比亚按蚊成蚊,与对照组比较,观察其对冈比亚按蚊死亡率和生殖率的影响. 结果膜饲免疫血浆的冈比亚按蚊的死亡率与对照组相比显著增高,死亡率增加56%;生殖率明显下降,实验组蚊虫平均产卵率为71.4个,对照组为88.1个,下降18.7%. 结论采用有效的方法分离蚊媒中肠的关键性抗原-中肠蛋白抗原可能成为抗蚊媒和其它抗媒介疫苗的靶抗原.     

抗醛糖还原酶单克隆抗体的制备与特性鉴定

目的:制备抗醛糖还原酶(AR)的单克隆抗体(mAb),并与本室制备的抗醛糖还原酶相似蛋白(ARL-1)mAb进行比较。方法:经RT-PCR获得AR基因,将基因插入pGEX-4T-1(His)6C中,构建重组质粒pGEX-4T-1(His)6C-AR,以重组质粒转化E.coliRosetta诱导表达GST-AR蛋白。以纯化的GST-AR蛋白免疫BALB/c小鼠,采用杂交瘤技术制备mAb。应用间接ELISA和Western blot方法对mAb进行筛选和鉴定。使用Clustalx和Antheprot软件,比较AR与ARL-1的同源性,表达GST-dAR[80~142氨基酸(aa)],与ARL-1差异较大;并分析AR的抗原性,表达GST-dA1(1~79aa)、GST-dA2(80~99aa)、GST-dA3(111~142aa)、GST-dA4(143~316aa)。利用AR全长及截短蛋白,采用Western blot分析制备的抗AR mAb识别AR抗原的部位。结果:获得3株稳定分泌抗AR mAb的杂交瘤细胞系ARB3、AR7B3G4和ARF10。3株抗GST-AR的mAb均为IgG1(κ型),腹水mAb效价为1∶4×105,细胞培养上清mAb效价为1∶1×104,3株mAb均可与胎盘组织中的AR蛋白起反应,而与GST-ARL-1和GST蛋白无交叉反应。它们分别为抗GST-dA1、GST-dA3和GST-dA4蛋白的mAb。结论:成功地制备了3株特异性抗AR mAb,可分别识别AR的1~79、111~142、143~316位氨基酸。将它们与抗ARL-1mAb联合应用,将有助于进一步研究AR与ARL-1蛋白的功能,并为深入探讨AR、ARL-1与相关疾病的关系及进行大规模的流行病学调查提供了有力的工具。     

抗戊型肝炎病毒重组蛋白单克隆抗体的制备和初步应用

目的:制备抗-戊型肝炎病毒的单克隆抗体,并将其用于分析戊型肝炎病毒不同毒株结构蛋白的抗原表位。方法:采用来自墨西哥株(Mexicanstrain)的戊型肝炎病毒重组蛋白(p166Mex)免疫Balb/c小鼠,取其脾细胞与SP2/0骨髓瘤细胞进行融合,经酶联免疫吸附试验(ELISA)法筛选阳性克隆,并将获得的单克隆抗体与戊型肝炎病毒缅甸株(Burmastrain)和美国株(USAstrain)的重组蛋白(p166Bur、p166US)进行交叉反应测定。结果:最终获得4株能稳定分泌抗-p166Mex的杂交瘤细胞株,即D8G10、E5E12、D4A3、B7E6。其中D8G10,E5E12和B7E6细胞株的培养上清液,还能分别与p166Bur和p166US重组蛋白发生阳性反应。结论:利用已获得的抗-p166Mex单克隆抗体,初步确定3种不同的戊型肝炎病毒重组蛋白(p166Bur、p166US、p166Mex)含有一种共同的抗原表位。     

等位基因特异PCR技术检测结核分支杆菌rpoB基因突变研究

目的 建立并评价等位特异多聚酶链反应检测结核分支杆菌耐利福平基因rpoB突变的方法。方法 设计与rpoB基因突变后的碱基配对的引物用于扩增突变基因，建立AS－PCR检测rpoB基因突变的方法，并对58株结核菌进行了检测。结果 AS－PCR检测结核菌耐利福平相关基因rpoB的敏感性为77.3%，特异性达91.7%。AS－PCR检测rpoB基因，有1628A→T、1657C→T，G和1673C→T突变分别占耐利福平结核菌株的18.2%，22.7%和36.4%。检测rpoB突变与MIC测定RFP耐药率和PCR－SSCP检测的总符合率分别为86.2%和74.1%。检测试验可在3－4h内完成。结论 AS－PCR方法是检测结核菌耐利福平基因突变的敏感和快速方法，可在临床实验室使用并为临床医师提供治疗依据。     

人膀胱癌T24细胞及其SCID小鼠移植瘤组织中KDR的表达

目的 检测KDR在人膀胱癌T24细胞及其SCID小鼠移植瘤组织中的表达。方法 常规培养T24细胞，建立荷人膀胱癌移植瘤SCID小鼠动物模型，使用抗KDR单克隆抗体，通过免疫荧光、免疫组化检测KDR在T24细胞及瘤体组织上的表达；结果 KDR在T24细胞及瘤体组织中均呈阳性表达。结论 本研究结果为进一步研究抗KDR单抗在荷T24细胞移植瘤动物体内分布及对瘤体生长的抑制效应奠定了实验基础。     

Immunogenicity study of low-dose administration of hepatitis B virus vaccine in newborn infants: A cost reduction trial

Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg-negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow-up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely.
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization.     

淋巴细胞恶性疾病HTLV-Ⅰ抗原及抗体的测定分析

本文以间接免疫萤光法测定96例淋巴细胞恶性患者血清中抗人T细胞白血病病毒Ⅰ型(HTLV—1)抗体。其中,80例急性淋巴细胞白血病;12例非何杰金氏淋巴瘤;4例慢性淋巴细胞白血病。发现一例成人抗HTLV—1抗体阳性,抗体滴度1:80,阳性率1.04％。並在培养细胞中检出HTLV—1抗原阳性细胞,前后两次阳性率分别为1.7～1.5％(P>0.05)。确诊病人已感染本病毒,提示HTLV—1已传入江西。认为测定HTLV—1抗原比抗体更重要,可用于早期确诊及游行病学调查。     

Isolation and characterization of a monoclonal anti-P30 antibody resistant mutant of Toxoplasma gondii

Of the possible iodine-labelled Toxoplasma gondii surface proteins, P30 (apparent Mr 30,000) is the principal one recognized by acute and convalescent anti-toxoplasma sera. This protein which comprises from 3 to 5% of the total parasite protein was used to raise a panel of parasiticidal monoclonal anti-P30 antibodies. One of these monoclonal antibodies was able to select a resistant mutant from a large population of chemically mutagenized wild-type P strain parasites. This mutant retained the wild type sensitivity to other non-P30 parasiticidal monoclonal antibodies as well as polyclonal anti-P30 rabbit sera. Analysis of surface radioiodinated wild type and mutant parasites showed that the mutant had a quantitative reduction in the amount of P30. A comparison of surface biotin labelled wild type and resistant parasites by two dimensional electrophoresis showed that the mutant lacked one and possibly two of several proteins that make up wild type P30. Western blot analysis indicated that the mutant was devoid of antigenically reactive P30. These findings further support the hypothesis that antigenic variants of T. gondii can be induced and may involve the major surface membrane antigens of the parasite.